SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs better-than-expected quarterly results and raised full-year revenue outlook sparked a sharp rally, with traders also pointing to growing backlog and quantum-computing demand. The upbeat reaction is tempered by debate over how much growth came from the SkyWater acquisition, as well as concerns about cash burn, dilution, and whether the gap-up can hold.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sustained weakness and underperformance amid a broader crypto selloff are driving discussion, with traders also concerned that political uncertainty could delay the CLARITY Act. Many blame Ripples token supply and question XRPs utility, while others view the decline as a buying opportunity and continue accumulating.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,194,930.21672838. The last known price of Ethereum is 2,237.04719652 USD and is down -0.08 over the last 24 hours. It is currently trading on 14276 active market(s) with $10,523,558,576.48 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereums sharp pullback and choppy rebound dominate discussion, with bearish traders warning that rallies may fail while bullish traders view the weakness as a buying opportunity and point to support holding. The community remains divided over whether the recovery can continue or the broader crypto-market slide will resume.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Debate over Snowflakes consumption-based model is driving attention, with traders warning that tighter budgets could lead customers to cut queries, storage and AI workloads, pressuring usage-linked revenue. Others see the models flexibility as a source of recovery when spending improves, while dip buyers and bearish traders remain divided on the stocks direction.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertivs stronger-than-expected quarterly results, raised outlook and more than doubled organic orders sparked a sharp rally, reinforcing optimism about demand for its data-center power and cooling systems. Some traders see confirmation that AI infrastructure spending remains robust, while skeptics point to permitting delays, financing risks and uncertainty over whether orders will translate into delivered revenue.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs post-earnings rally is drawing attention as traders focus on improved profitability and cash generation, along with managements ability to address upcoming debt with cash rather than dilution. Bulls see a potential turnaround and speculate about a short squeeze, while skeptics point to declining revenue and continued weakness at BetterHelp.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Anticipation around clinical readoutsespecially CTX310s Phase 1b data and zugo-cel updatesis the dominant discussion, alongside debate over CRISPRs quarterly results and CASGEVYs commercial ramp. Traders are hopeful strong data could support a partnership or improve the pipeline outlook, while skeptics question whether positive developments will break the stocks long-running range.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp, volatile selloff is driving attention to Strategy as a leveraged BTC proxy, with traders debating whether the weakness could deepen the stocks losses. Bears also cite dilution, preferred-stock obligations and a possible MSCI removal as risks, while bulls argue the pullback is a buying opportunity and look for a rebound.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Fords quarterly earnings beat and higher lower-end profit guidance are driving discussion, with bulls citing improving profitability and the dividend while skeptics question why the shares have struggled to hold gains and point to cost pressures and weak sales. Traders are also watching whether the stock can clear nearby resistance after the post-earnings move.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention after quarterly results beat expectations, with Alani Nu growth and international expansion offsetting a decline in the flagship Celsius brand. Traders welcomed the beat and stock rebound, but some question how durable the growth is and point to weaker core-brand sales and compressed margins.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre...

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre...

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026...

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA PR Newswire NEW YORK, May 26, 2026...

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that develops therapies for patients...

ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that...

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.

ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026...

Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 22, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) securities between May...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Atara is jointly developing the drug with Pierre Fabre Pharmaceuticals.</li><li>The FDA stated that a single-arm study using a historical control group could support a future marketing application.</li><li>FDA had rejected an initial application submitted by Atara in January 2026, raising concerns about the trial design and analysis.</li></ul>Shares of Atara Biotherapeutics (ATRA) surged more than 43% in morning trade on Thursday, recording their biggest single-day gains in more than two years, after the biotech firm announced a promising update from the U.S. Food and Drug Administration (FDA) tied to its experimental blood cancer therapy.<a href="https://stocktwits.com/symbol/ATRA">ATRA shares</a> also breached the 100-day moving average (100-DMA) for the first time in nearly four months.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AATRA"><img src="https://news.stocktwits-cdn.com/ATRA_jpg_7fc3a2b23b.webp" alt="ATRA.jpg"></a>Source: TradingView<h2 class="st-heading-2">FDA Talks Signal Resubmission Hopes For ATRA’s Immunotherapy</h2>Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application (BLA) for Tabelecleucel. The drug is used for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).The update followed a recent Type A meeting between the FDA, Atara, and its partner, Pierre Fabre Pharmaceuticals, after the agency issued a Complete Response Letter (CRL) earlier this year, stating that it could not approve the application in its current form.However, the FDA has now stated that a single-arm study using a historical control group could support a future marketing application. Pierre Fabre plans to include updated results from its Phase 3 study, including additional patient data and longer follow-up, as part of the resubmission package.Atara and Pierre Fabre are jointly developing the drug.<h2 class="st-heading-2">Why Did FDA Reject ATRA’s Initial Application?</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/atra-rises-on-pushing-for-meeting-with-fda-on-rare-disease-drug-rejection/cZdeli8RIP1">previously</a> declined to approve Tabelecleucel, stating the company’s study did not provide enough evidence for accelerated approval and raised concerns about the trial design and analysis.Pierre Fabre responded to the agency, providing additional explanations and arguing that the study was properly controlled and suitable to support the application. The company also submitted updated long-term efficacy data, along with supportive development and European post-marketing data, for a potential resubmission.<h2 class="st-heading-2">Retail Skeptical About ATRA’s Rally</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.However, one user stated the news did not justify the rally.<stembedurl>https://stocktwits.com/robanbieber/message/652581236</stembedurl>Another user called ATRA’s chart setup “neutral” and saw support between $6.50 and $7.<stembedurl>https://stocktwits.com/independentresearch1/message/652578353</stembedurl>ATRA shares have been under heavy selling pressure this year, slumping nearly 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-bulls-shrug-off-earnings-loss-retail-traders-eye-a-crucial-fda-deadline/cZXbg96ReQT">IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$ATRA Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration 
https://www.businesswire.com/news/home/20261014012366/en/Atara-Biotherapeutics-Reports-that-the-Resubmitted-Tabelecleucel-Tab-cel-Biologics-License-Application-Has-Been-Accepted-by-the-U.S.-Food-and-Drug-Administration 
Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027

TwongStocks

$ATRA   Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

james olson

$ATRA Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATRA Atara Biotherapeutics Inc

Fundamentals

Latest ATRA News